NeoGenomics (NEO) has been on a downward spiral lately with significant selling pressure. After declining 29.2% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscil ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Sc ...

Core Insights - Laboratory Corp reported second-quarter 2025 adjusted earnings per share of $4.35, an increase from $3.94 a year ago, surpassing the consensus estimate of $4.17 [1] - Sales rose 9.5% year-over-year to $3.53 billion, exceeding the consensus of $3.485 billion, driven by organic revenue growth of 5.4%, acquisitions net of divestitures of 3.5%, and foreign currency translation of 0.6% [1] - Adjusted operating income for the quarter was $531.6 million, representing 15.1% of revenue [1] Financial Guidance - LabCorp raised its fiscal year 2025 adjusted earnings guidance from $15.70-$16.40 to $16.05-$16.50, compared to the consensus of $16.09 [3] - The company also increased 2025 sales guidance from $13.978 billion-$14.148 billion to $14.08 billion-$14.23 billion, compared to the consensus of $13.897 billion [3] - Forecasted sales growth for 2025 is now 7.5%-8.6%, up from prior guidance of 6.7%-8% [3] Segment Performance - The guidance includes 2025 Diagnostics Laboratories sales growth of 7%-8%, an increase from prior guidance of 6.5%-7.7% [4] - Biopharma Laboratory Services sales growth is now projected at 6.1%-7.5%, compared to prior guidance of 3.0%-5.0% [4] Market Reaction - Laboratory Corp's stock increased by 11.3% to $278.91 following the earnings report [5] - Organic growth trends in Labcorp's diagnostics segment improved quarter-over-quarter, although slightly below consensus expectations [5] Acquisitions - Labcorp announced an agreement to acquire select assets of Incyte Diagnostics' clinical and anatomic pathology testing businesses in the Pacific Northwest [7] - The company is progressing with the acquisition of select oncology and clinical testing assets from BioReference Health [7] - Labcorp acquired select assets of the outreach business from Community Health Systems across 13 states for $195 million in cash [7]

Labcorp Holdings (LH) Q2 2025 Earnings Call July 24, 2025 09:00 AM ET Company ParticipantsChristin O’Donnell - VP - Investor RelationsAdam Schechter - President, CEO, Chairman & DirectorJulia Wang - EVP & CFOKevin Caliendo - Managing DirectorPatrick Donnelly - Managing DirectorLisa Gill - Managing DirectorElizabeth Anderson - Senior MDTycho Peterson - MD - Global EquitiesLuke Sergott - Director - Healthcare Equity ResearchMichael Ryskin - Managing DirectorConference Call ParticipantsMichael Cherny - Senior ...

Labcorp Holdings (LH) Q2 2025 Earnings Call July 24, 2025 09:00 AM ET Speaker0Good day and thank you for standing by. Welcome to the Q2 twenty twenty five LabCorp Holdings Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone.You will then hear an automated message advising your hand is raised. To withdraw your question ...

Second Quarter 2025 Supplemental Financial Information 1 Use of Adjusted Measures The company has provided in this presentation and accompanying tables "adjusted" financial information that has not been prepared in accordance with GAAP, including adjusted net income, adjusted EBITDA, adjusted EPS (or adjusted net income per share), adjusted operating income, adjusted operating margin, free cash flow, and certain segment information. The company believes these adjusted measures are useful to investors as a s ...

Raises Full-Year Guidance BURLINGTON, N.C., July 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended June 30, 2025 and raised full-year guidance. "Labcorp had a very strong second quarter, delivering double-digit topline growth, while expanding margins across both segments," said Adam Schechter, chairman and CEO of Labcorp. "We brought innovative tests to market, and applied our leadership in s ...

Quest Diagnostics Inc. DGX delivered a robust second quarter in 2025, exceeding analyst expectations with strong sales and earnings growth, prompting an upward revision to its full-year guidance.However, the diagnostic test provider flagged potential headwinds from ongoing tariffs and the significant financial impact if the Protecting Access to Medicare Act (PAMA) is not deferred, setting the stage for a watchful eye on legislative and trade developments.For the second quarter of 2025, the company reported ...

Quest Diagnostics (DGX) Q2 2025 Earnings Call July 22, 2025 08:30 AM ET Company ParticipantsShawn Bevec - VP - IRJames Davis - Chairman, CEO, President & DirectorSam Samad - EVP & CFOKevin Caliendo - Managing DirectorElizabeth Anderson - Senior MDPatrick Donnelly - Managing DirectorNoah Kava - Equity Research AssociateConference Call ParticipantsAnn Hynes - MD & Senior Healthcare Services Equity AnalystErin Wright - AnalystMichael Cherny - Senior MD & Senior Research AnalystPito Chickering - AnalystJack Mee ...

Quest Diagnostics (DGX) Q2 2025 Earnings Call July 22, 2025 08:30 AM ET Speaker0Welcome to the Quest Diagnostics Second Quarter twenty twenty five Conference Call. At the request of the company, this call is being recorded. The entire contents of this call, including the presentation and question and answer session that will follow, are the copyrighted property of Quest Diagnostics with all rights reserved. Any redistribution, retransmission or rebroadcast of this call in any form without the written consen ...